A Boston-based start-up for ag-biotech has raised$ 26.5 % to develop a vaccine to reduce livestock methane emissions. Yes, actually. A company is really trying to develop a vaccine to stop cow farts. On its website, ArkeaBio describes itself as a” start-up ag biotech company” developing a secure, user-friendly, and cost-conscious vaccine to reduce animal methane emissions that will work smoothly with existing international agribusiness practices. ” When it comes to climate change, a plain vaccine can be a strong tool”, the biotech company says. Indeed, a fictional vaccine against climate change is currently being developed. There is an almost universal vaccine for everything. Any conceivable reasons why it might kill cows? They want that, but MAYBE.
Startup raises$ 26.5 million for vaccine to stop cow farts and burps https ://t.co/Cswmlj5eN8— Ann Maga ( @LAnnBlume1 ) May 12, 2024 Who’s behind the effort to vaccinate cattle to stop them from farting? None other than Bill Gates. ” ArkeaBio, a Boston developer of a vaccine to reduce livestock methane emissions, raised a$ 26.5 million in venture capital funding led by an investment fund founded by Bill Gates”, Axios reports. Bill Gates designing a vaccine against … cow farts Climate’s the hustle of the century, up there with the “food pyramid” and central banking https ://t.co/bMJd0CQ86S— Peter St Onge, Ph. D. ( @profstonge ) May 12, 2024Per Axios: Caring about cow farts ( or burps ) has become a political punchline, but they’re estimated to create more than 5 % of global greenhouse gasses. Vaccines could be a somewhat low- cost, flexible solution, particularly as food demand increases. In terms of trapping ambient heat, methane is much more effective than carbon dioxide, but it also decomposes more quickly. Breakthrough Energy Ventures led the Series A circular, and was joined by Grantham Foundation, AgriZeroNZ, Rabo Ventures, Overview Capital and The51 Food &, AgTech Fund. BEV recently funded ArkeaBio’s$ 12 million seed round. In December 2022, PRNewswire reported that Arkea Bio Corp. ( ArkeaBio ), a pioneer in developing technology to reduce greenhouse gas ( GHG ) emissions from the agricultural sector, today closed a$ 12 million seed series financing round led by Breakthrough Energy Ventures ( BEV ). BEV was founded by Bill Gates and has been supported by a number of world’s leading businessmen. It stated in the press release that it has raised more than$ 2 billion in committed capital to support cutting-edge businesses that are achieving net-zero emissions. In an interview with CNBC, Carlisel Roberts, the co-chair of the investment committee at Bill Gates ‘ climate fund, stated that he anticipates the Inflation Reduction Act to spur entrepreneurship and support startups. pic. twitter.com/O9yOW11D5S— NowThis Impact ( @nowthisimpact ) August 17, 2022Bloomberg reports: Ag- biotech company ArkeaBio says its drug targets methane- producing microorganisms that live in animals ‘ saliva and gastrointestinal tracks. It’s also in its early stages right now, and it needs at least 2.5 more years before it can go on the market. But if successful, the drug would be a step towards tackling one of the world’s most insurmountable climate challenges: curbing methane emissions from agriculture. According to the International Energy Agency, the industry produces the most human-generated methane, back of fossil fuels and waste. The tools to make a really good run at this did n’t exist until the cost of sequencing and biotechnology had dropped significantly over the past five to ten years, according to Colin South, chief executive officer of ArkeaBio. The company is seeing “better- than- expected results” in cattle trials now afoot, he added. Researchers and startups have been experimenting with various feed additives, including biochar and seaweed, to reduce animal methane emissions. The powerful greenhouse gas has been created by others as cattle masks. While many of the world’s largest producers of dairy and beef have expressed an interest in enticing their suppliers to use methane-reducing feed additives, some have actually followed through on any level, according to a Bloomberg investigation last year. According to South, existing agricultural supply channels could be used to distribute a vaccine, noting that beef and dairy cattle now receive a wide range of medications to treat respiratory illnesses, bovine diarrhea, and other ailments. According to Feedstuffs, one of the most pressing issues facing the agrarian sector today is the reduction of methane emissions, according to Chris Rivest, chairman of ArkeaBio and partner at Breakthrough Energy Ventures. ArkeaBio’s method employs cutting-edge vaccine technologies to produce potent, robust solutions to reduce on-farm methane emissions, he added, giving them a unique opportunity to change the agrarian landscape in the future. Investors have been paying close attention to the development of the first methane-reducing vaccine, which was developed for secure and quick application within existing on-farm practices, as a result of the research and development results from Feedstuffs. The funding raised through this Series A financing will be crucial in expanding the scope of vaccine research, development, and deployment, including extensive field trials and involvement along the supply chain. ” We are thankful for the economic support, confidence, and trust of our investors. This funding will make it easier to develop our vaccine-based solution to a pressing world issue, according to CEO Colin South of ArkeaBio. The Grantham Foundation’s statement,” Climate change is the greatest challenge humanity has always faced,” is true. It is the race of our lives.’ This funding will allow us to keep developing the tools farmers need to achieve world-wide reductions in livestock methane emissions. ArkeaBio is committed to working with industry partners, governmental bodies, and environmental groups to bring this novel solution to market. CLICK HERE to read more about ArkeaBio. [[{“value”:”
A Boston-based start-up in agbiotech has raised $26.5 Million to develop a vaccine that will reduce livestock methane emissions. Yes, really. There is a company that is trying to develop a vaccine for cow farts. ArkeaBio, an agbiotech startup, is developing a vaccine that is safe, cost-effective, and user-friendly to reduce ruminant emissions of methane. This vaccine will work seamlessly with current global agribusiness practice,” ArkeaBio says on its website. The biotech company claims that a simple vaccine could be a powerful tool when it comes to tackling climate change. There is a vaccine being developed for a fictional climate change. There is a vaccine for everything. Anyone think it could kill cows? Maybe that’s what they want. Startup raises $26.5 million for vaccine to stop cow farts and burps https://t.co/Cswmlj5eN8 — Ann Maga (@LAnnBlume1) May 12, 2024 Who’s behind the effort to vaccinate cattle to stop them from farting? Bill Gates. Axios reported that “ArkeaBio,” a Boston-based developer of a vaccine for reducing livestock methane emission, raised $26.5 million from an investment fund founded Bill Gates. Bill Gates designing a vaccine against… cow farts Climate’s the hustle of the century, up there with the “food pyramid” and central banking https://t.co/bMJd0CQ86S — Peter St Onge, Ph.D. (@profstonge) May 12, 2024 Per Axios: Caring about cow farts (or burps) has become a political punchline, but they’re estimated to create more than 5% of global greenhouse gasses. Vaccines are a low-cost and scalable solution that could be used, especially as the demand for food increases. Methane is more powerful than carbon dioxide in terms of trapping heat in the atmosphere, but it also dissipates faster. Breakthrough Energy Ventures led this Series A round. It was joined by Grantham Foundation AgriZeroNZ Rabo Ventures Overview Capital The51 Food & AgTech Fund. BEV had previously funded ArkeaBio’s $12 million seed funding round. In December 2022, PRNewswire reported that “Arkea Bio Corp.’s (ArkeaBio) pioneering technology to reduce greenhouse gases (GHGs) from the agricultural sector announced today the successful closing of a $12 Million Seed Series financing led by Breakthrough Energy Ventures” (BEV). BEV, founded by Bill Gates with the support of many top business leaders around the world, has raised over $2 billion in committed funding to support cutting-edge businesses that are leading the way to net-zero emission,” according to a press release. Carmichael Roberts is the co-leader for the investment committee of Bill Gates’ climate funds, Breakthrough Energy Ventures. He told CNBC in an interview that he believes the Inflation Reduction Act will drive entrepreneurship and help startups. pic.twitter.com/O9yOW11D5S — NowThis Impact (@nowthisimpact) August 17, 2022 Bloomberg reports: Ag-biotech company ArkeaBio says its drug targets methane-producing microorganisms that live in animals’ saliva and digestive tracks. It’s still early in the development process and it will take at least 2.5 more years before it can be put on the market. If the drug is successful, it could be a step in tackling one of climate change’s most difficult challenges: reducing methane emissions. According to the International Energy Agency, the industry is responsible for more human-generated methane than fossil fuels or waste. “The tools for making a really good go at this didn’t exist until the cost sequencing and cost of biotechnology dropped substantially over the past five to ten years,” said Colin South. Chief executive officer of ArkeaBio. The company is seeing “better-than-expected results” in cattle trials currently underway, he added. Researchers and startups have been testing different feed additives, including seaweed and Biochar, to reduce animal methane emission. Others have developed masks for cattle that capture the powerful greenhouse gas. Bloomberg’s investigation of last year found that while many of the biggest buyers of beef and dairy products in the world have expressed an interest in encouraging suppliers to use feed additives that reduce methane, few actually followed through. South noted that a vaccine could be distributed via existing agricultural supply channels. Dairy and beef cattle are already given a variety of drugs to prevent respiratory disease, bovine diarrhea, and other ailments. According to Feedstuffs, Chris Rivest, Chairman at ArkeaBio, and partner at Breakthrough Energy Ventures said that reducing methane emissions in the agricultural sector was one of the biggest challenges facing the fight against climate changes today. “ArkeaBio will use innovative vaccine technologies to create effective and massively scaleable solutions to reduce methane on-farm emissions,” he said. ArkeaBio’s research and development has attracted considerable attention from investors. The methane-reducing vaccination is designed to be implemented safely and quickly within existing farm practices. The funds raised through this Series A financing are expected to play a crucial role in expanding research, development, and deployment of the methane-reducing vaccine, including large scale field trials and engagement throughout the supply chain. “We are grateful for the financial support and confidence of our investors. This funding will speed up the development of our vaccine to address a pressing global issue,” said Colin South. CEO of ArkeaBio. Climate change is the greatest threat humanity has ever faced, as The Grantham Foundation stated. It’s a race for our lives. This capital raise will allow us to continue creating the tools needed by farmers to achieve globally relevant cuts in livestock methane emission. Click HERE to read more from ArkeaBio.
“}]]
